IL297362A - Using surfactant protein d to treat viral infections - Google Patents

Using surfactant protein d to treat viral infections

Info

Publication number
IL297362A
IL297362A IL297362A IL29736222A IL297362A IL 297362 A IL297362 A IL 297362A IL 297362 A IL297362 A IL 297362A IL 29736222 A IL29736222 A IL 29736222A IL 297362 A IL297362 A IL 297362A
Authority
IL
Israel
Prior art keywords
rhsp
pharmaceutical composition
sars
calcium
protein
Prior art date
Application number
IL297362A
Other languages
English (en)
Hebrew (he)
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of IL297362A publication Critical patent/IL297362A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL297362A 2020-04-22 2021-04-20 Using surfactant protein d to treat viral infections IL297362A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013726P 2020-04-22 2020-04-22
US202063072354P 2020-08-31 2020-08-31
PCT/US2021/028207 WO2021216584A1 (en) 2020-04-22 2021-04-20 Use of surfactant protein d to treat viral infections

Publications (1)

Publication Number Publication Date
IL297362A true IL297362A (en) 2022-12-01

Family

ID=78270057

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297362A IL297362A (en) 2020-04-22 2021-04-20 Using surfactant protein d to treat viral infections

Country Status (10)

Country Link
US (1) US20230181697A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138905A4 (cg-RX-API-DMAC7.html)
JP (1) JP7798791B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019089A (cg-RX-API-DMAC7.html)
AU (1) AU2021258178A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180205A1 (cg-RX-API-DMAC7.html)
IL (1) IL297362A (cg-RX-API-DMAC7.html)
MX (1) MX2022013195A (cg-RX-API-DMAC7.html)
WO (1) WO2021216584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118369582A (zh) * 2022-01-31 2024-07-19 积水医疗株式会社 包含肺表面活性蛋白的液态组合物和包含所述液态组合物的免疫测定试剂盒以及肺表面活性蛋白的保存稳定性提高方法
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
US6838428B2 (en) 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
JP7798471B2 (ja) 2017-09-06 2026-01-14 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質d(sp-d)を調製するための方法及び組成物
WO2019050857A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC METHODS, COMPOSITIONS AND CELLS FOR PREPARING D SURFACTORY PROTEIN (SP-D)
RU2020131642A (ru) * 2018-03-29 2022-04-29 Эйрвэй Терапьютикс, Инк. Способы и композиции, содержащие сурфактантный белок d (sp-d)
MX2020010031A (es) 2018-03-29 2021-01-08 Airway Therapeutics Inc Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
CN112481417B (zh) * 2020-12-24 2022-05-27 山西大学 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒

Also Published As

Publication number Publication date
US20230181697A1 (en) 2023-06-15
JP7798791B2 (ja) 2026-01-14
JP2023523253A (ja) 2023-06-02
EP4138905A4 (en) 2024-04-17
WO2021216584A1 (en) 2021-10-28
BR112022021423A2 (pt) 2023-01-03
KR20230019089A (ko) 2023-02-07
MX2022013195A (es) 2023-01-05
CA3180205A1 (en) 2021-10-28
EP4138905A1 (en) 2023-03-01
AU2021258178A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
IL264254A (en) In vitro methods for increasing viability of immune-cells
IL272361B1 (en) Antibodies that bind active alpha-synuclein
NZ582888A (en) Charged lipoprotein complexes and their uses
CN102772787A (zh) 促胰岛素肽的稳定制剂
IL295167A (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
IL295551A (en) Method for selection of high m6p recombinant proteins
WO2010045479A1 (en) Phospholipid micellar and liposomal compositions and uses thereof
CN102834115B (zh) 用于治疗流感的重组人cc10蛋白
IL297336A (en) Methods for the treatment of serious conditions by lipid binding complexes of basic proteins
CN113201068A (zh) 基因重组抗2019-nCoV和其它冠状病毒IgY及其小分子抗体以及应用
IL302066A (en) Lipopeptide fusion inhibitors as sars-cov-2 antivirals
Wang et al. ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses
Shin et al. Multivalent display of ApoAI peptides on the surface of tobacco mosaic virus nanotubes improves cholesterol efflux
Sun et al. Engineered MEVs for photoreceptor-targeted delivery of USP25 to alleviate diabetic retinopathy
JP7798791B2 (ja) ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用
IL296960A (en) Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof and method using the same
IL297250A (en) Modified mini-nucleosome core proteins and use in nucleic acid delivery
Almarhoun et al. Overexpression of STARD3 attenuates oxidized LDL-induced oxidative stress and inflammation in retinal pigment epithelial cells
Chen et al. Novel perspectives on Nanotechnological and biomedical implications of monotherapy or combination regimen of lactoferrin
IL268971B2 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
IL301088A (en) Ribitol treatment
WO2021247756A1 (en) Recombinant human cc10 protein for treatment of influenza, ebola, and coronavirus
IL302126A (en) Preparations that include tetrahydrocannabinol for the treatment of acute respiratory failure and/or acute respiratory distress syndrome
TWI877962B (zh) 載脂蛋白j拮抗肽用於製備促進脂質分解作用及減緩相關症候群之醫藥組成物的用途
US20100267627A1 (en) Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same